Meta-analyses: a method to maximise the evidence from clinical studies?

被引:12
作者
Maier, Wolfgang [1 ]
Moeller, Hans-Juergen [2 ]
机构
[1] Univ Bonn, Dept Psychiat & Psychotherapy, D-53105 Bonn, Germany
[2] Univ Munich, Dept Psychiat & Psychotherapy, D-80336 Munich, Germany
关键词
Meta-analyses; Evidence-based medicine; Clinical studies; SEROTONIN REUPTAKE INHIBITORS; STATISTICAL TESTS; NEW-GENERATION; PUBLICATION; EFFICACY; TRIALS; BIAS; ANTIDEPRESSANTS; ANTIPSYCHOTICS; SUICIDE;
D O I
10.1007/s00406-009-0068-3
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
Evidence-based medicine (EBM) is becoming the guiding principle for clinical treatment decisions. But evidence remains a loosely defined term. Multiple criteria for evidence criteria have been proposed. Most influential evidence criteria give priority to meta-analyses because they promise an objective procedure to combine the outcomes of all informative, putatively conflicting studies on the same issue in an overall score. However, we claim that meta-analyses are of limited informative value for the following six reasons: (1) meta-analyses are often "overpowered" with clinically irrelevant results that might emerge as highly significant; (2) there is serious concern of publication biases with "negative" studies not being published; (3) meta-analyses consider the variation in the results of the empirical studies included to be random noise, however, the variability of results across studies can be informative; (4) the result of a meta-analysis depends on the strategy used to identify the included empirical studies; (5) the quality of conclusions from meta-analyses depends on the statistical tests used to combine the results of the separate studies; (6) the qualitative conclusions drawn from the meta-analytical combination of individual studies may depend on specific design aspects of the individual studies. Thus, meta-analyses are primarily a method to generate hypotheses through an a posteriori analysis of treatment effects.
引用
收藏
页码:17 / 23
页数:7
相关论文
共 35 条
[1]   The revised CONSORT statement for reporting randomized trials: Explanation and elaboration [J].
Altman, DG ;
Schulz, KF ;
Moher, D ;
Egger, M ;
Davidoff, F ;
Elbourne, D ;
Gotzsche, PC ;
Lang, T .
ANNALS OF INTERNAL MEDICINE, 2001, 134 (08) :663-694
[2]  
Anderson I M, 1998, Depress Anxiety, V7 Suppl 1, P11, DOI 10.1002/(SICI)1520-6394(1998)7:1+<11::AID-DA4>3.0.CO
[3]  
2-I
[4]   Selective serotonin reuptake inhibitors versus tricyclic antidepressants: a meta-analysis of efficacy and tolerability [J].
Anderson, IM .
JOURNAL OF AFFECTIVE DISORDERS, 2000, 58 (01) :19-36
[5]  
[Anonymous], 2009, NAT I HLTH CLIN EXC
[6]   How to grade categories of evidence [J].
Bandelow, Borwin ;
Zohar, Joseph ;
Kasper, Siegfried ;
Moeller, Hans-Juergen .
WORLD JOURNAL OF BIOLOGICAL PSYCHIATRY, 2008, 9 (04) :242-247
[7]   World Federation of Societies of Biological Psychiatry (WFSBP) Guidelines for the Pharmacological Treatment of Anxiety, Obsessive-Compulsive and Post-Traumatic Stress Disorders - First Revision [J].
Bandelow, Borwin ;
Zohar, Joseph ;
Hollander, Eric ;
Kasper, Siegfried ;
Moeller, Hans-Juergen ;
Allgulander, Christer ;
Ayuso-Gutierrez, Jose ;
Baldwin, David ;
Bunevicius, Robertas ;
Cassano, Giovanni ;
Fineberg, Naomi ;
Gabriels, Loes ;
Hindmarch, Ian ;
Kaiya, Hisanobu ;
Klein, Donald F. ;
Lader, Malcolm ;
Lecrubier, Yves ;
Lepine, Jean-Pierre ;
Liebowitz, Michael R. ;
Lopez-Ibor, Juan Jose ;
Marazziti, Donatella ;
Miguel, Euripedes C. ;
Oh, Kang Seob ;
Preter, Maurice ;
Rupprecht, Rainer ;
Sato, Mitsumoto ;
Starcevic, Vladan ;
Stein, Dan J. ;
van Ameringen, Michael ;
Vega, Johann .
WORLD JOURNAL OF BIOLOGICAL PSYCHIATRY, 2008, 9 (04) :248-312
[8]  
BAUER M, 2004, BIOL BEHANDLUNG UNIP
[9]   Committee for Medicinal Products for Human Use (CHMP) assessment on efficacy of antidepressants [J].
Broich, Karl .
EUROPEAN NEUROPSYCHOPHARMACOLOGY, 2009, 19 (05) :305-308
[10]   Bias, Spin, and Misreporting: Time for Full Access to Trial Protocols and Results [J].
Chan, An-Wen .
PLOS MEDICINE, 2008, 5 (11) :1533-1535